<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A651D4E4-AD1C-41FF-B0F4-515D328DCBC5"><gtr:id>A651D4E4-AD1C-41FF-B0F4-515D328DCBC5</gtr:id><gtr:name>Open Source Instruments</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A651D4E4-AD1C-41FF-B0F4-515D328DCBC5"><gtr:id>A651D4E4-AD1C-41FF-B0F4-515D328DCBC5</gtr:id><gtr:name>Open Source Instruments</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CD120AEA-FB8C-4583-B0C3-A460490BE9F3"><gtr:id>CD120AEA-FB8C-4583-B0C3-A460490BE9F3</gtr:id><gtr:firstName>Dimitri</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Kullmann</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EB67724E-4289-450D-9C33-0BBB426146F7"><gtr:id>EB67724E-4289-450D-9C33-0BBB426146F7</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/25A55E6B-3FCD-4B79-AE52-D49CE4138B7E"><gtr:id>25A55E6B-3FCD-4B79-AE52-D49CE4138B7E</gtr:id><gtr:firstName>Stephanie</gtr:firstName><gtr:surname>Schorge</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802158"><gtr:id>AED67184-2879-4F7A-BFA7-0BD8D6BC0EB6</gtr:id><gtr:title>Lentiviral potassium channel expression to treat focal neocortical epilepsy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802158</gtr:grantReference><gtr:abstractText>Epilepsy affects approximately 300,000 people in the UK, of whom about 100,000 do not respond to available medication. An especially severe form of drug-resistant epilepsy (focal neocortical epilepsy) often occurs when seizures arise from a small area of abnormal tissue in the brain. Because the rest of the brain is often intact, it should be possible to alter the excitability of neurons in the abnormal area to stop seizures arising or to terminate them when they occur. We have validated an experimental model of focal neocortical epilepsy and have done much ground-work to use modified viruses to change the expression of individual genes in neurons. We propose to reduce the excitability of neurons in the seizure focus, or alternatively to enhance the excitability of inhibitory neurons. Our work will build on preliminary data that we have obtained by studying the consequences of rare neurological disease caused by mutations of genes that encode ion channels, proteins that underlie the electrical signalling of individual neurons.</gtr:abstractText><gtr:technicalSummary>Focal neocortical epilepsy is among the most difficult forms of epilepsy to treat: it is very often refractory to available drugs, and the seizure focus is amenable to surgical resection in only a minority of cases. We have previously validated an experimental model of this disorder, which recapitulates its main features including continuous or near-continuous seizure activity and resistance to drugs that are effective in other epilepsy models. The seizures do however respond to focal drug delivery, showing that this disease is, in principle, treatable with more targeted methods of altering the excitability of neurons. We will capitalise on our complementary expertise in epileptology, cellular biophysics and molecular biology to test novel therapeutic strategies based on viral delivery of K+ channels into the seizure focus. We will express Kv1.1 and Kir2.1 (which we have previously studied in the context of neurological channelopathies) to lower the excitability of neurons in the seizure focus and/or reduce neurotransmitter release from their terminals. In parallel, we will also use promoters that are active in interneurons to drive the expression of a dominant-negative K+ channel mutant in interneurons, in order to raise their excitability and enhance neurotransmitter release from their terminals. The effectiveness of these strategies will be monitored by taking advantage of a new wireless video-EEG rodent telemetry facility that we have established.</gtr:technicalSummary><gtr:fund><gtr:end>2012-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>826574</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>SS and MCW</gtr:description><gtr:id>D8E461D5-73D1-446C-9B3A-180D53F485E9</gtr:id><gtr:impact>grants awarded</gtr:impact><gtr:outcomeId>N4zVawz81Nu-1</gtr:outcomeId><gtr:partnerContribution>Expertise in molecular biology and epilepsy models</gtr:partnerContribution><gtr:piContribution>collaboration to develop new treatment for focal epilepsy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Open Source Instruments</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>OpenSourceInstruments</gtr:description><gtr:id>C2D1669A-BCA4-4819-9198-EA38A1CC960B</gtr:id><gtr:impact>Extensive details available at http://www.opensourceinstruments.com/SCT/</gtr:impact><gtr:outcomeId>saQUnHNAGUa-1</gtr:outcomeId><gtr:partnerContribution>Facility for improved EEG detection and analysis</gtr:partnerContribution><gtr:piContribution>We have entered into a highly successful collaboration with OpenSourceInstruments (K Hashemi) based at Brandeis University. This has led to the development of a wireless EEG telemetry system that has been adopted by several other groups around the world, including Dr Louise Upton at Oxford. The designs are freely accessible under the GNU open licence.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Work experience at ION</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D3BA0EFA-E536-4C7B-B6E0-E8265EE6E9EF</gtr:id><gtr:impact>Both students were well-engaged with basic and clinical research at the Institute of Neurology.

Social Mobility Fund and the Worshipful Company of Pewterers have both indicated they'd be delighted to carry on with the scheme in future years.</gtr:impact><gtr:outcomeId>545cee2167be22.60723829</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DIS visits from students</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>58D7C635-0647-4E02-9295-4336B31CE264</gtr:id><gtr:impact>International undergraduate students (20-30) with the DIS programme in Copenhagen visit ION at Queen Square, hear a presentation and tour the Department, and discuss careers in science with the team.</gtr:impact><gtr:outcomeId>56d581a135faa7.63764229</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015,2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at Royal Society summer science festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>99449EC2-1BBD-4C25-BA5B-8290C621779A</gtr:id><gtr:impact>I gave a presentation &amp;quot;Brain Hacking With Viruses&amp;quot; introducing the concepts of Gene therapy for epilepsy at the Royal Society Summer Science Festival. The talk was repeated 4 times, and was well attended by students from around the UK. I also raised some of the ethical and safety concerns of the approach and got very strong feedback in the questions that students were interested even if the testing involved use of animals in research.</gtr:impact><gtr:outcomeId>58bfdd7415bc71.47016996</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>https://royalsociety.org/science-events-and-lectures/2016/07/schools-talk-schorge-tuesday/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pint of Science presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>02E275D8-878E-4DF1-996C-8B7C7AAFA67F</gtr:id><gtr:impact>This was for general public with an audience of about 30.

Raised public profile of research via talk and website</gtr:impact><gtr:outcomeId>5391afdda2e869.40399593</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit (Lenox)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>10D4791B-B59D-453E-8174-530CACC06E49</gtr:id><gtr:impact>This was a presentation on Gene Therapy and treatments of epilepsy to a High School audience in the states.</gtr:impact><gtr:outcomeId>56d58120084d72.23193808</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2468066</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L01095X/1</gtr:fundingRef><gtr:id>0AD02E09-4308-4DF4-B707-353D27CD0B90</gtr:id><gtr:outcomeId>5391aef16f5047.18846982</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Investigaotr Award</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>6C55808B-9E0F-4A3E-98D9-97D29DAB2D1F</gtr:id><gtr:outcomeId>NahxWragNmP0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>FP7 grant</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>602130</gtr:fundingRef><gtr:id>583C9D6C-1DE2-4982-B331-6B126E2AD582</gtr:id><gtr:outcomeId>S9zeoGpJ41K</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L003457/1</gtr:fundingRef><gtr:id>93281079-432E-4978-A0CA-1D68E433280A</gtr:id><gtr:outcomeId>nU5LwgtHeJh</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ONO Pharmaceuticals Pilot funding</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Ono Pharmaceutical</gtr:fundingOrg><gtr:id>40F93BDC-8EC3-44A6-A78A-E167C9AC82B5</gtr:id><gtr:outcomeId>58bfde52210bc9.08944544</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called &amp;quot;DREADD&amp;quot; receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.</gtr:description><gtr:grantRef>G0802158</gtr:grantRef><gtr:id>9297EE2B-0DA8-46DD-AB0F-9C5FFCE95C28</gtr:id><gtr:impact>We are seeking investment to take this to clinical trials</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56de9afd0feab1.73010480</gtr:outcomeId><gtr:patentId>WO2015136247</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>COMBINED USE OF A VECTOR ENCODING A MODIFIED RECEPTOR AND ITS EXOGENOUS AGONIST IN THE TREATMENT OF SEIZURES</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Queen Square award for implemenation of 3Rs in Research</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>8A63E423-6846-4C84-9B27-5C71195ED78E</gtr:id><gtr:impact>We are working to change our local attitudes towards working with animals in research. We presented this award to the then Cabinet Minister, and it was recognised as a high level local engagement with the 3Rs in animal work. All students presenting their scientific posters at the symposium are now aware that they must also explain their measures to improve 3Rs to our NACWO, including justifying the model used.</gtr:impact><gtr:outcomeId>545cf7b705dfa7.82947698</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Appointed to Epilepsy Research UK Science Advisory Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CAA29889-B4C5-4B48-B560-C7D315F9F4E0</gtr:id><gtr:outcomeId>SerM8N2aJeo</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of SACGM(CU)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A2CBA28A-7230-4666-98D8-AA3975E319E0</gtr:id><gtr:outcomeId>XCt38jp2yYa</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Sarentis</gtr:companyName><gtr:description>Start-up founded by Dr Denise Barbut, New York</gtr:description><gtr:id>3599A28A-D4B2-4296-92B6-93ACD792E663</gtr:id><gtr:impact>Sarentis is currently seeking investment to take our gene therapy into clinical trials</gtr:impact><gtr:outcomeId>56e027b58b87f4.58324067</gtr:outcomeId><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>64BAC718-D379-48AD-A163-BF425A08F3A9</gtr:id><gtr:title>Gene therapy in epilepsy-is it time for clinical trials?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4758</gtr:issn><gtr:outcomeId>546238598afdd2.88501117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB925BBA-8C49-4D0A-8EA6-B9A8994BACEC</gtr:id><gtr:title>Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2748097c5a93b216cbf5bf41ebdbb3ad"><gtr:id>2748097c5a93b216cbf5bf41ebdbb3ad</gtr:id><gtr:otherNames>Fletcher EV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>s8TQ7YWjSEn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED29F777-04C7-4476-973A-4D3C62D7ECD1</gtr:id><gtr:title>The clinical and genetic heterogeneity of paroxysmal dyskinesias.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b6f09a6640fea0ca88338ba7ed5668"><gtr:id>f9b6f09a6640fea0ca88338ba7ed5668</gtr:id><gtr:otherNames>Gardiner AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56de9a2dcd6de9.36202092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8B4C426-4EEF-4CBB-92CA-FEB689E3B75B</gtr:id><gtr:title>Long-term potentiation in hippocampal oriens interneurons: postsynaptic induction, presynaptic expression and evaluation of candidate retrograde factors.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ae2a25850360f65ec63f35761b26fa8"><gtr:id>1ae2a25850360f65ec63f35761b26fa8</gtr:id><gtr:otherNames>Nicholson E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>54623859f075f8.27337908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46690B34-A614-42F0-8267-4A83E61641F1</gtr:id><gtr:title>Independent regulation of basal neurotransmitter release efficacy by variable Ca&amp;sup2;+ influx and bouton size at small central synapses.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dee3b9490f57d9ac4d64b01c8d5be195"><gtr:id>dee3b9490f57d9ac4d64b01c8d5be195</gtr:id><gtr:otherNames>Ermolyuk YS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>pm_15917_27_23049481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA674BA8-0304-4422-854A-D14745E786AF</gtr:id><gtr:title>What's wrong with the amygdala in temporal lobe epilepsy?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>MWWEVBsx6W3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A82166CE-E9E3-4888-8D6F-D967D73A5234</gtr:id><gtr:title>Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd004fe7995fd24fab161f71a958a5af"><gtr:id>cd004fe7995fd24fab161f71a958a5af</gtr:id><gtr:otherNames>Gilbert GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>KwQQMQgSSxE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>378AD7D7-6676-4E84-8E41-D5BEE8172679</gtr:id><gtr:title>Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb8609980b875605d79eaad613f6e13b"><gtr:id>eb8609980b875605d79eaad613f6e13b</gtr:id><gtr:otherNames>St?dberg T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56de979b3587f1.57290205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F4A682F-5638-4CE2-9B36-98EAFF0F0F1E</gtr:id><gtr:title>Nerve excitability studies characterize Kv1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/085b7423079ef5c45c18095ee05f5a73"><gtr:id>085b7423079ef5c45c18095ee05f5a73</gtr:id><gtr:otherNames>Tomlinson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>bUPxoxeDdin</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BBF33F0-370B-4493-BA76-1117C75E6D94</gtr:id><gtr:title>Induction of Anti-Hebbian LTP in CA1 Stratum Oriens Interneurons: Interactions between Group I Metabotropic Glutamate Receptors and M1 Muscarinic Receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f1f054a23850a0fa11dfd04fb4f1335"><gtr:id>3f1f054a23850a0fa11dfd04fb4f1335</gtr:id><gtr:otherNames>Le Duigou C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>56de979b6cfe66.40737390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EAA58A2-CD10-4B5C-9FAE-1D6092D82F92</gtr:id><gtr:title>Interneuron networks in the hippocampus.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-4388</gtr:issn><gtr:outcomeId>e8ESUCcrPUk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFB0CC53-065C-44D4-8F0B-4DF744312015</gtr:id><gtr:title>Gene therapy in status epilepticus.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f13d4d30c5a901bebc5dc995df7dfd5b"><gtr:id>f13d4d30c5a901bebc5dc995df7dfd5b</gtr:id><gtr:otherNames>Walker MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5462385a26a9e0.15463034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2C1B0CA-BFE0-44FC-AC95-E8AF1B564974</gtr:id><gtr:title>Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.</gtr:title><gtr:parentPublicationTitle>Muscle &amp; nerve</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4a622948ab7690627e2ef7352ddf2e"><gtr:id>cb4a622948ab7690627e2ef7352ddf2e</gtr:id><gtr:otherNames>Finlayson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0148-639X</gtr:issn><gtr:outcomeId>pm_15917_27_23281026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B0EC00D-F0C5-46FD-874D-967F5084F6CC</gtr:id><gtr:title>From treatment to cure: stopping seizures, preventing seizures, and reducing brain propensity to seize.</gtr:title><gtr:parentPublicationTitle>International review of neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1dfdefb4f074acaad26adccba29954d"><gtr:id>b1dfdefb4f074acaad26adccba29954d</gtr:id><gtr:otherNames>Pavlov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0074-7742</gtr:issn><gtr:outcomeId>5437e5f4011ba3.17747675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E574BFBC-8DE4-4632-8C95-9B246192D7A1</gtr:id><gtr:title>Optogenetic approaches to treat epilepsy.</gtr:title><gtr:parentPublicationTitle>Journal of neuroscience methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab5d922700c9e9c3deb2ccbcc87b9667"><gtr:id>ab5d922700c9e9c3deb2ccbcc87b9667</gtr:id><gtr:otherNames>Wykes RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0165-0270</gtr:issn><gtr:outcomeId>56de979b107c69.73663239</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FE308C1-4E32-4D85-9123-A88515C50D33</gtr:id><gtr:title>Plasticity of inhibition.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5860e115fb39bc53662cfaa7f12d6a"><gtr:id>db5860e115fb39bc53662cfaa7f12d6a</gtr:id><gtr:otherNames>Kullmann DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_15917_27_22998865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EB2D404-A957-4281-9B4D-8C9D90F7C107</gtr:id><gtr:title>Genetic neurological channelopathies: molecular genetics and clinical phenotypes.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f804d3e647f618a01cc6307129f5106"><gtr:id>6f804d3e647f618a01cc6307129f5106</gtr:id><gtr:otherNames>Spillane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>56de979ba15253.82581735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>440F1B9F-587A-408F-8FBA-3ED880986FDA</gtr:id><gtr:title>Lambert-Eaton syndrome IgG inhibits transmitter release via P/Q Ca2+ channels.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f804d3e647f618a01cc6307129f5106"><gtr:id>6f804d3e647f618a01cc6307129f5106</gtr:id><gtr:otherNames>Spillane J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56de979ad62959.70136579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D2F93BE-ADB4-4365-A91C-B8DE9D649573</gtr:id><gtr:title>Autoimmune synaptopathies.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6837a62e3d7c04b652a506c6ef070db6"><gtr:id>6837a62e3d7c04b652a506c6ef070db6</gtr:id><gtr:otherNames>Crisp SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>56de979bcda398.42101723</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CFDF09C-2131-47F4-BACD-A693F92741ED</gtr:id><gtr:title>Spike-timing dependent plasticity in inhibitory circuits.</gtr:title><gtr:parentPublicationTitle>Frontiers in synaptic neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/771dec6e39674e34ffad5286ff5cef53"><gtr:id>771dec6e39674e34ffad5286ff5cef53</gtr:id><gtr:otherNames>Lamsa KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1663-3563</gtr:issn><gtr:outcomeId>L7GqPsrJsGe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A3D215F-2940-4B2B-96DE-65DDCCB1BF3C</gtr:id><gtr:title>MicroRNAs in epilepsy: pathophysiology and clinical utility.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f9c246e0daf7e391c652184c2ed6f2c"><gtr:id>2f9c246e0daf7e391c652184c2ed6f2c</gtr:id><gtr:otherNames>Henshall DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>5885f1621ea9b3.45225453</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0619014-F3DD-4504-9430-FC175F9C0DFB</gtr:id><gtr:title>Evaluating first seizures in adults in primary care.</gtr:title><gtr:parentPublicationTitle>The Practitioner</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d395a8a7eab5b4d34040d5f391c1164"><gtr:id>4d395a8a7eab5b4d34040d5f391c1164</gtr:id><gtr:otherNames>Mantoan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0032-6518</gtr:issn><gtr:outcomeId>FtE9FdezDzH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3291068-BBB0-4F76-8ED1-D07761C4B0E8</gtr:id><gtr:title>Endogenous zinc depresses GABAergic transmission via T-type Ca(2+) channels and broadens the time window for integration of glutamatergic inputs in dentate granule cells.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6242653e54e571ca915edf1023490a45"><gtr:id>6242653e54e571ca915edf1023490a45</gtr:id><gtr:otherNames>Grauert A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>pm_540e162e162fed4d0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBC3C4C9-DE64-45DE-873A-4D802A529B01</gtr:id><gtr:title>Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches.</gtr:title><gtr:parentPublicationTitle>Epilepsy &amp; behavior : E&amp;B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106f4de0efaf314f1d2b93eb968d6960"><gtr:id>106f4de0efaf314f1d2b93eb968d6960</gtr:id><gtr:otherNames>Rosenow F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-5050</gtr:issn><gtr:outcomeId>5a2fd7b06cc386.10433599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17364F9C-055C-45FD-9FD7-B61FE1696F46</gtr:id><gtr:title>NONGENETIC FACTORS INFLUENCE SEVERITY OF EPISODIC ATAXIA TYPE 1 IN MONOZYGOTIC TWINS</gtr:title><gtr:parentPublicationTitle>NEUROLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6436138bf0b09fb013df7c2d82e1148c"><gtr:id>6436138bf0b09fb013df7c2d82e1148c</gtr:id><gtr:otherNames>Graves Tracey D.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5a36097f67d2a4.61280763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFCC4AAD-1DA0-4A76-95CF-F6C29EF86C74</gtr:id><gtr:title>Central nervous system histoplasmosis in an immunocompetent patient.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb0a8b16aa776f53413c2aa9f59b14c3"><gtr:id>fb0a8b16aa776f53413c2aa9f59b14c3</gtr:id><gtr:otherNames>Tai YF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>YWhwetRbs2E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64766395-C316-4390-BC92-FC9959BA1CDA</gtr:id><gtr:title>Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab5d922700c9e9c3deb2ccbcc87b9667"><gtr:id>ab5d922700c9e9c3deb2ccbcc87b9667</gtr:id><gtr:otherNames>Wykes RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_14982_22_23147003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B6624A8-978B-407E-89BF-9DA8B9AE5A0D</gtr:id><gtr:title>GABAA receptor mutations in epilepsy (commentary on Lachance-Touchette et al.).</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e5ddd5dcaa4de64212db06858b662189"><gtr:id>e5ddd5dcaa4de64212db06858b662189</gtr:id><gtr:otherNames>Reid CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>pvAGPdekeNG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>290DE7CD-47BF-46EF-BE80-2635733B0C9F</gtr:id><gtr:title>Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14632e9fec0b4b9b740218552a278537"><gtr:id>14632e9fec0b4b9b740218552a278537</gtr:id><gtr:otherNames>Rajakulendran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>ngN9GXNpRo9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4D5F35F-183C-43F5-ADEF-DE388EE1457F</gtr:id><gtr:title>Group I mGluR agonist-evoked long-term potentiation in hippocampal oriens interneurons.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f1f054a23850a0fa11dfd04fb4f1335"><gtr:id>3f1f054a23850a0fa11dfd04fb4f1335</gtr:id><gtr:otherNames>Le Duigou C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>dRsFkjf6tfo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48357A11-5DBF-4651-8F92-23C77E0B893E</gtr:id><gtr:title>Mapping out hippocampal inhibition.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1720c9310e979d84f014606ac327cda3"><gtr:id>1720c9310e979d84f014606ac327cda3</gtr:id><gtr:otherNames>Oren I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>pm_15917_27_22362104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E22CE45-ED5F-44D3-9B6F-FFAEA5996B17</gtr:id><gtr:title>Enhanced QT shortening and persistent tachycardia after generalized seizures.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01763fa8b34ad46c6421049627308ae1"><gtr:id>01763fa8b34ad46c6421049627308ae1</gtr:id><gtr:otherNames>Surges R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>doi_55f984984f5558ca</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DF1040F-7F0A-42F3-BBB6-0C839151FBF2</gtr:id><gtr:title>How much inhibition in an epileptiform burst?</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1dfdefb4f074acaad26adccba29954d"><gtr:id>b1dfdefb4f074acaad26adccba29954d</gtr:id><gtr:otherNames>Pavlov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>cgJjaB8XuEy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C62B5CD-E82A-440D-9303-27A5F3E2508B</gtr:id><gtr:title>In vivo impact of presynaptic calcium channel dysfunction on motor axons in episodic ataxia type 2.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/085b7423079ef5c45c18095ee05f5a73"><gtr:id>085b7423079ef5c45c18095ee05f5a73</gtr:id><gtr:otherNames>Tomlinson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56de979c022f19.86414357</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>685AE5D6-F220-4040-B79A-E0A4B9B1BEEF</gtr:id><gtr:title>In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/085b7423079ef5c45c18095ee05f5a73"><gtr:id>085b7423079ef5c45c18095ee05f5a73</gtr:id><gtr:otherNames>Tomlinson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_15917_27_23065794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>579C570D-3E79-41C1-84A9-54DDE921CF13</gtr:id><gtr:title>Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches.</gtr:title><gtr:parentPublicationTitle>Epilepsy &amp; behavior : E&amp;B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11cfc9f68998668035eaff80a6b973f6"><gtr:id>11cfc9f68998668035eaff80a6b973f6</gtr:id><gtr:otherNames>Bauer S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-5050</gtr:issn><gtr:outcomeId>5a34f1677550e2.25034688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA20BF0E-E46C-4F57-99BA-C21E6076F203</gtr:id><gtr:title>Short- and long-term depression at glutamatergic synapses on hippocampal interneurons by group I mGluR activation.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f1f054a23850a0fa11dfd04fb4f1335"><gtr:id>3f1f054a23850a0fa11dfd04fb4f1335</gtr:id><gtr:otherNames>Le Duigou C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>PbsQv1xU6a1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C716467-D746-4C21-A5EB-2A248AB1EAE5</gtr:id><gtr:title>Sodium channel mutations and epilepsy: association and causation.</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7fccc55a62cf97212e1cfed26905242"><gtr:id>f7fccc55a62cf97212e1cfed26905242</gtr:id><gtr:otherNames>Schorge S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>TRupefXTN38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6E45553-60F6-47B6-843C-7494D5FCC5F7</gtr:id><gtr:title>I(h)-mediated depolarization enhances the temporal precision of neuronal integration.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1dfdefb4f074acaad26adccba29954d"><gtr:id>b1dfdefb4f074acaad26adccba29954d</gtr:id><gtr:otherNames>Pavlov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>VCxhvHmG8Xm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9D78E60-15BA-4951-81BB-1BFBFF525B89</gtr:id><gtr:title>Cortical inhibition, pH and cell excitability in epilepsy: what are optimal targets for antiepileptic interventions?</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1dfdefb4f074acaad26adccba29954d"><gtr:id>b1dfdefb4f074acaad26adccba29954d</gtr:id><gtr:otherNames>Pavlov I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>pm_15917_27_22890709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2B35E7F-E86B-4A6A-BBE8-DF85EC0C71B0</gtr:id><gtr:title>Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86694d88fb2c9bb553f0bfcfc3584548"><gtr:id>86694d88fb2c9bb553f0bfcfc3584548</gtr:id><gtr:otherNames>Graves TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>djJ3r9t4Hhj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>832BE31A-D3F6-44DA-8B5D-B300999F1AF7</gtr:id><gtr:title>Commonalities in epileptogenic processes from different acute brain insults: Do they translate?</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d851b9818bbf90260902d2fcf3bc3bf"><gtr:id>3d851b9818bbf90260902d2fcf3bc3bf</gtr:id><gtr:otherNames>Klein P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>5a37dcdbd49a73.59448040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31A1D929-E9A7-4CF6-9A4A-F15623658670</gtr:id><gtr:title>Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/085b7423079ef5c45c18095ee05f5a73"><gtr:id>085b7423079ef5c45c18095ee05f5a73</gtr:id><gtr:otherNames>Tomlinson SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_15917_27_23349320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8824701C-0D61-448D-B7D3-175CE63720DA</gtr:id><gtr:title>Chemical-genetic attenuation of focal neocortical seizures.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e71c4ba694ccab7ce7b6754c5c8856a6"><gtr:id>e71c4ba694ccab7ce7b6754c5c8856a6</gtr:id><gtr:otherNames>K?tzel D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>54623858f031f2.58887089</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46E7EF69-2ED1-45FC-90FB-99E3EE94D2D4</gtr:id><gtr:title>Dysfunction of the Ca(V)2.1 calcium channel in cerebellar ataxias.</gtr:title><gtr:parentPublicationTitle>F1000 biology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14632e9fec0b4b9b740218552a278537"><gtr:id>14632e9fec0b4b9b740218552a278537</gtr:id><gtr:otherNames>Rajakulendran S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1757-594X</gtr:issn><gtr:outcomeId>i7rzvxHKFUP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1105ABA9-BD56-4796-A8C2-55D64B3B06B0</gtr:id><gtr:title>PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b6f09a6640fea0ca88338ba7ed5668"><gtr:id>f9b6f09a6640fea0ca88338ba7ed5668</gtr:id><gtr:otherNames>Gardiner AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_15917_27_23077024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94F88672-9368-4F38-A8F8-D8F9A990114F</gtr:id><gtr:title>N-methyl-D-aspartate receptor antibody-mediated encephalitis.</gtr:title><gtr:parentPublicationTitle>British journal of hospital medicine (London, England : 2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa41d5a54770b22355ce31312ea5b54c"><gtr:id>fa41d5a54770b22355ce31312ea5b54c</gtr:id><gtr:otherNames>Mehta S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1750-8460</gtr:issn><gtr:outcomeId>pm_15917_27_22875528</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802158</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>